Biofrontera
BFRIW
4 hedge funds and large institutions have $46.7K invested in Biofrontera in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 0 closing their positions.
0.67% less ownership
Funds ownership: 1.66% → 0.99% (-0.67%)
20% less funds holding
Funds holding: 5 → 4 (-1)
66% less capital invested
Capital invested by funds: $136K → $46.7K (-$89.3K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.73K |
| 2 |
CS
Clear Street
New York
|
-$748 |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$704 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
1
Bard Associates
Chicago,
Illinois
| $40.4K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $4.24K | -$704 | -1,742 | -8% |
|
|
CS
3
Clear Street
New York
| $2K | -$748 | -1,850 | -14% |
|
|
4
UBS Group
Zurich,
Switzerland
| $2 | -$1.73K | -4,273 | -100% |
|
BFRIW Hedge Fund Activity: Q4 2022 in Review
4 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Biofrontera (BFRIW) for Q4 2022, worth a combined $46.7K — down 66% from $136K a quarter earlier.
Fund positioning in BFRIW was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was UBS Group, cutting an estimated $1.73K.
- 4 institutional investors held Biofrontera (BFRIW) as of Q4 2022, down from 5 in Q3 2022.
- Funds reported $46.7K of Biofrontera stock for Q4 2022, down 66% quarter-over-quarter.
- 0 funds opened new Biofrontera positions in Q4 2022 and 0 closed out.
- The largest Biofrontera seller in Q4 2022 was UBS Group, an estimated $1.73K sold.
Based on aggregated 13F filings for Q4 2022.